20 (AIDX) Current Deferred Revenue (2024 - 2026)

20 (AIDX) posted Current Deferred Revenue of $487722.0 for Q1 2026, up 6.8% on a QoQ basis from $456687.0 in Q4 2025.

20 (AIDX) Current Deferred Revenue (2024 - 2026) Analysis & Trends

20's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $487722.0 for Q1 2026.

Quarterly Current Deferred Revenue changed N/A year-over-year to $487722.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $487722.0 (changed N/A YoY) and the FY2025 annual result came in at $456687.0, down 12.25% from the prior year.
Current Deferred Revenue was $487722.0 for Q1 2026 at 20, up from $456687.0 in the prior quarter.
Across five years, Current Deferred Revenue topped out at $520451.0 in Q4 2024 and bottomed at $456687.0 in Q4 2025.
A 3-year average of $488286.7 and a median of $487722.0 in 2026 frame the typical range for Current Deferred Revenue.
Peak annual rise in Current Deferred Revenue reached 12.25% in 2025, while the deepest fall reached 12.25% in 2025.
20's Current Deferred Revenue stood at $520451.0 in 2024, then fell by 12.25% to $456687.0 in 2025, then rose by 6.8% to $487722.0 in 2026.
Business Quant data shows AIDX's Current Deferred Revenue at $487722.0 in Q1 2026, $456687.0 in Q4 2025, and $520451.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	20	3.91 Mn	-313,912.28	62,884.00

Download Data